title: Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?
abstract: Prostate cancer is common all around the world. Hormonal therapy is the mainstay of therapy, however castration-resistant prostate cancer (CRPC) becomes a serious problem and needs further clinical trials with novel agents. Novel agents like cabazitaxel, abireterone acetate or enzalutamide are encouraging but we do not know which one is the best in metastatic CRPC. In here, treatment modalities for metastatic CRPC are discussed witha mini-review of the literature.
authors: Dept of Medical Oncology, Ankara Numune Training and Research Hospital, Altindag, Ankara, Turkey E-mail : gokmenumut@hotmail.com.
authors: Mutlu
authors: M
authors: Dogan
authors: Gokmen Umut
authors: GU
authors: Erdem
authors: Nurullah
authors: N
authors: Zengin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000592:standards*; D006801:Humans; D008297:Male; D015990:Placebo Effect; D011379:Prognosis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality; D012107:Research Design; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents